Compare Endeavour Silver Corp (EXK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs BIO-TECHNE Corp — how do they compare? Endeavour Silver Corp trades at $7.45 (market cap $2.36B), while BIO-TECHNE Corp trades at $71.79 (market cap $11.14B). The key difference: BIO-TECHNE Corp is far larger — about 4.7× Endeavour Silver Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| EXK | TECH | |
|---|---|---|
Market Cap | $2.36B | $11.14B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $71.48 |
52-Week Low | $4.96 | $43.31 |
Enterprise Value | $2.36B | $11.22B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXK trades at $7.47, down 7.55% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 production of 3.4 million silver equivalent ounces and beat Q1 2026 earnings estimates with $0.21 EPS versus $0.10 expected. Despite negative net income margins and ROE, revenue growth is projected to improve from $468M in 2025 to $614M in 2026. Analyst sentiment remains positive with 78.57% buy ratings.
The outlook is mixed: operational momentum and silver price trends offer upside, but profitability challenges and high valuation ratios pose risks. Investors should weigh strong production growth against persistent negative earnings and cash flow concerns in a volatile commodity market.
Bio-Techne (TECH) trades at $71.69, up 0.65% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, though RSI indicates potential overbought conditions. Fundamentally, revenue held at $1.22B in 2025, but net income fell to $73.40M with margin compression. Analysts are split 50/50 buy/hold with a $67.75 consensus target, below the current price, reflecting acquisition uncertainty.
The outlook hinges on the Merck deal closure at $73.00, offering a 1.8% premium from current levels. Risks include shareholder litigation challenging the transaction's fairness and regulatory approval delays. Without the deal, high P/E of 102.12 and declining profitability pose downside risks. The acquisition provides a near-term floor, but execution volatility remains a concern for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
